TOKYOMEDIJAPAN MEDICAL REFERENCE
⌕ Search databaseOfficial source · PMDA / MHLW
Rx · Reference only · no online purchase

Jardiance (Empagliflozin)

Jardiance / Empagliflozin. Used for type 2 diabetes; the 10 mg product is also used for certain chronic heart failure and kidney disease.

PMDAproduct-level source2025-09label updated2026-10-05site verified
ジャディアンス錠10mg/25mg · 10 mg
Japanese product photo · 10 mg · ベーリンガーインゲルハイム
Main useUsed for type 2 diabetes; the 10 mg product is also used for certain chronic heart failure and kidney disease.A brief overview of Japanese approved uses. Check the PMDA label below for product-specific conditions.
Japan product name
ジャディアンス錠10mg/25mg
Brand
Jardiance
Generic name
Empagliflozin
Japanese generic name
エンパグリフロジン
Chinese name
恩格列净
Marketing authorization holder
日本ベーリンガーインゲルハイム株式会社
Strengths
10 mg / 25 mg
Dosage form
tablet
Therapeutic area
Metabolic
Regulatory status
Rx
Label updated
2025-09
TOKYO MEDI verified
2026-10-05
MEDICINE REFERENCE

Detailed product reference

Summaries refer to the listed Japanese product. Eligibility, adjustments and full risks depend on its label and strength; a clinician determines individual treatment.

01

Product overview

Jardiance is a selective SGLT2 inhibitor; Japanese 10 mg products also have heart-failure and kidney-disease uses.

Read source section ↗
02

Mechanism of action

Reduces renal glucose reabsorption and affects sodium/fluid handling.

Read source section ↗
03

Japanese indications & eligibility

10/25 mg: type 2 diabetes. 10 mg: selected chronic heart failure and chronic kidney disease, excluding terminal renal failure/dialysis.

Read source section ↗
04

Administration & dose differences

Usually 10 mg once daily before/after breakfast; diabetes may be escalated to 25 mg. Heart/kidney uses remain 10 mg.

Read source section ↗
05

Adverse effects & key risks

Risks include volume depletion, urinary/genital infection and ketoacidosis, sometimes without marked hyperglycemia.

Read source section ↗
06

Contraindications & special populations

Contraindications include severe ketosis/coma, serious infection, perioperative states, severe trauma and hypersensitivity.

Read source section ↗
07

Drug interactions

Insulin/sulfonylureas increase hypoglycemia risk; diuretics may increase volume depletion.

Read source section ↗
08

Assessment & monitoring

Monitor renal function, volume status, blood pressure, glucose and infection or ketoacidosis symptoms.

Read source section ↗
09

Storage & handling

Store at room temperature. The photo is the Japanese 10 mg blister.

Read source section ↗
10

Sources & verification

Product checked ·

Official source

These links go directly to PMDA records for this Japanese product. Professional and patient-facing sources are separated.